Status:
UNKNOWN
A Study of Dayingpian Treating Bipolar Disorder
Lead Sponsor:
Shanghai Mental Health Center
Conditions:
Bipolar Disorder
Eligibility:
All Genders
14-65 years
Brief Summary
The main purpose of this cohort study is to evaluate the efficiency and safety of Dayingpian to provide evidence-based medical evidence for the subsequent drug development.
Detailed Description
Dayingpian is a kind of formula in traditional Chinese medicine with the effect of promoting blood circulation and reducing blood stasis. It has been prescribed as an add-on in the treatment of mental...
Eligibility Criteria
Inclusion
- Meets the International Classification of Diseases-10(ICD-10) criteria for Bipolar Disorder.
- Outpatients or inpatients in Shanghai Mental Health Center.
- Male or female subjects aged 14-65 years.
- education of Junior high school or above.
- The patient fully understands and signs the informed consent form.
Exclusion
- Apparent violent aggression/suicide within the last two weeks.
- Other patients that the investigator believes should not be included in the study.
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
308 Patients enrolled
Trial Details
Trial ID
NCT05247593
Start Date
August 1 2022
End Date
September 1 2024
Last Update
October 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China, 200030